Melanoma and nonmelanoma skin cancer in patients with multiple tumours - Evidence for new syndromes in a population-based study

British Journal of Dermatology

Volumn 150, Issue 3, 2004, Pages 531-536

  Nielsen, K ^a   Ingvar, C ^a   Masback A ^a   Westerdahl, J ^a   Borg, A ^a   Sandberg, T ^a   Jonsson, N ^a   Nagel, J ^a   Olsson, H ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CDKN2A; CMM and associated tumours; Multiple melanoma; Mutation analysis; NMSC; p16

Indexed keywords

PROTEIN P16;

ADULT; AGE; AGED; ARTICLE; CANCER REGISTRY; CDKN2A GENE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; HUMAN TISSUE; MALE; MELANOMA; MENINGIOMA; MULTIPLE CANCER; NEURINOMA; NONMELANOMA SKIN CANCER; POPULATION RESEARCH; PRIORITY JOURNAL; SKIN CANCER; SWEDEN; SYNDROME; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; FEMALE; GENES, P16; HUMANS; MALE; MELANOMA; MENINGIOMA; MIDDLE AGED; MUTATION; NEOPLASMS, MULTIPLE PRIMARY; NEURILEMMOMA; RISK FACTORS; SKIN NEOPLASMS; SWEDEN; SYNDROME;

EID: 1842454307     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2003.05852.x     Document Type: Article

References (42)

1. Hemminki K, Vaittinen P, Kyyronen P. Age-specific familial risks in common cancers of the offspring. Int J Cancer 1998; 78: 172-5.
2. Savoia P, Quaglino P, Verrone A, Bernengo MG. Multiple primary melanomas: analysis of 49 cases. Melanoma Res 1998; 8: 361-6.
3. Sorensen SA, Jensen OA, Klinken L. Familial aggregation of neuroectodermal and gastrointestinal tumors. Cancer 1983; 52: 1977-80.
4. Tucker MA, Fraser MC, Goldstein AM et al. Risk of melanoma and other cancers in melanoma-prone families. J Invest Dermatol 1993; 100 (Suppl.): 350S-355S.
5. Hashemi J, Platz A, Ueno T et al. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas. Cancer Res 2000; 60: 6864-7.
6. Johnson TM, Hamilton T, Lowe L. Multiple primary melanomas. J Am Acad Dermatol 1998; 39: 422-7.
7. MacKie RM, Andrew N, Lanyon WG, Connor JM. CDKN2A germline mutations in U.K. patients with familial melanoma and multiple primary melanomas. J Invest Dermatol 1998; 111: 269-72.
8. Sun S, Pollock PM, Liu L et al. CDKN2A mutation in a non-FAMMM kindred with cancers at multiple sites results in a functionally abnormal protein. Int J Cancer 1997; 73: 531-6.
9. Cannon-Albright LA, Kamb A, Skolnick M. A review of inherited predisposition to melanoma. Semin Oncol 1996; 23: 667-72.
10. Bhatia S, Estrada-Batres L, Maryon T et al. Second primary tumours in patients with cutaneous malignant melanoma. Cancer 1999; 86: 2014-20.
11. Borg A, Sandberg T, Nilsson K et al. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 2000; 92: 1260-6.
12. Gutman M, Cnaan A, Inbar M et al. Are malignant melanoma patients at higher risk for a second cancer? Cancer 1991; 68: 660-5.
13. Rabkin CS, Biggar RJ, Melbye M, Curtis RE. Second primary cancers following anal and cervical carcinoma: evidence of shared etiologic factors. Am J Epidemiol 1992; 136: 54-8.
14. Retsas S, Mohith A, Bell J et al. Melanoma and additional primary cancers. Melanoma Res 2000; 10: 145-52.
15. Volk N, Pompe-Kirn V. Second primary cancers in breast cancer patients in Slovenia. Cancer Causes Control 1997; 8: 764-70.
16. Wassberg C, Thorn M, Yuen J et al. Second primary cancers in patients with cutaneous malignant melanoma: a population-based study in Sweden. Br J Cancer 1996; 73: 255-9.
17. Mattsson B. Cancer Registration in Sweden Studies on Completeness and Validity of Incidence and Mortality Registers [Doctorial Thesis]. Stockholm: Karolinska Institute, Sweden, 1984.
18. Mattsson B, Rutqvist LE, Wallgren A. Undernotification of diagnosed cancer cases to the Stockholm Cancer Registry. Int J Epidemiol 1985; 14: 64-9.
19. IARC. IARC/IACR Cancer Registration Principles and Methods. Chapters 6 and 7. Lyon: IARC. 1991.
20. Hawkins MM. Multiple primary cancers in population-based cancer registries. Eur J Cancer 1996; 32A: 1279-80.
21. Borg A, Johannsson U, Johannsson O et al. Novel germline p16 mutation in familial malignant melanoma in southern Sweden. Cancer Res 1996; 56: 2497-500.
22. Giles G, Staples M, McCredie M, Coates M. Multiple primary melanomas: an analysis of cancer registry data from Victoria and New South Wales. Melanoma Res 1995; 5: 433-8.
23. Lal G, Liu L, Hogg D et al. Patients with both pancreatic adenocarcinoma and melanoma may harbor germline CDKN2A mutations. Genes Chromosomes Cancer 2000; 27: 358-61.
24. Levi F, Randimbison L, Te VC, La Vecchia C. Non-Hodgkin's lymphomas, chronic lymphocytic leukaemias and skin cancers. Br J Cancer 1996; 74: 1847-50.
25. Monzon J, Liu L, Brill H et al. CDKN2A mutations in multiple primary melanomas. N Engl J Med 1998; 338: 879-87.
26. Scheibner A, Milton GW, McCarthy WH et al. Multiple primary melanoma - a review of 90 cases. Australas J Dermatol 1982; 23: 1-8.
27. Wassberg C, Thorn M, Yuen J et al. Cancer risk in patients with earlier diagnosis of cutaneous melanoma in situ. Int J Cancer 1999; 83: 314-17.
28. Bahuau M, Vidaud D, Jenkins RB et al. Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors. Cancer Res 1998; 58: 2298-303.
29. Randerson-Moor JA, Harland M, Williams S et al. A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum Mol Genet 2001; 10: 55-62.
30. Eliezer Robinson ATM. Skin Cancers and Melanoma. In: Multiple Primary Cancers (Neugut AI, ed.). Philadelphia: Lippincott Williams & Wilkins, 1999; 484.
31. Stoll BA, ed. Risk Factors and Multiple Cancer. New York: John Wiley and Sons, 1994.
32. Wei Q, Matanoski GM, Farmer ER et al. DNA repair related to multiple skin cancers and drug use. Cancer Res 1994; 54: 437-40.
33. Goldstein AM, Fraser MC, Struewing JP et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 1995; 333: 970-4.
34. Haluska FG, Hodi FS. Molecular genetics of familial cutaneous melanoma. J Clin Oncol 1998; 16: 670-82.
35. Kamb A, Gruis NA, Weaver-Feldhaus J et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264: 436-40.
36. Whelan AJ, Bartsch D, Goodfellow PJ. Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med 1995; 333: 975-7.
37. Nobori T, Miura K, Wu DJ et al. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368: 753-6.
38. Padmore RF, Lara JF, Ackerman DJ et al. Primary combined malignant melanoma and ductal carcinoma of the breast. A report of two cases. Cancer 1996; 78: 2515-25.
39. Peiffer SL, Bartsch D, Whelan AJ et al. Low frequency of CDKN2 mutation in endometrial carcinomas. Mol Carcinogen 1995; 13: 210-12.
40. Harland M, Holland EA, Ghiorzo P et al. Mutation screening of the CDKN2A promoter in melanoma families. Genes Chromosomes Cancer 2000; 28: 45-15.
41. Stratton SP, Dorr RT, Alberts DS. The state-of-the-art in chemoprevention of skin cancer. Eur J Cancer 2000; 36: 1292-7.
42. Yarbrough WG, Aprelikova O, Pei H et al. Familial tumor syndrome associated with a germline nonfunctional p16INK4a allele. J Natl Cancer Inst 1996; 88: 1489-91.